Advances in diagnosis and treatment of combined hepatocellular-cholangiocarcinoma
10.3760/cma.j.cn115396-20240409-00108
- VernacularTitle:混合型肝细胞-胆管细胞癌的诊疗进展
- Author:
Shui LIU
1
;
Jiyao SHENG
;
Xuewen ZHANG
Author Information
1. 吉林大学第二医院肝胆胰外科 吉林省肝胆胰疾病转化医学工程实验室，长春 130041
- Keywords:
Neoplasms, complex and mixed;
Diagnosis;
Therapeutic uses;
Combined hepatocellular-cholangiocarcinoma;
Individualized therapy
- From:
International Journal of Surgery
2024;51(4):223-228
- CountryChina
- Language:Chinese
-
Abstract:
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a special type of primary liver cancer, which is characterized by dual phenotypic differentiation of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Due to the lack of specific diagnostic markers and therapeutic targets, the preoperative diagnosis is difficult, the treatment is not easy, and the prognosis is poor. Routine serology, imaging examination and histological biopsy are the main methods of preliminary screening and diagnosis of cHCC-CC. Patients with resectable cHCC-CC should be treated with surgical treatment if possible, but whether they should receive liver transplantation remains a careful choice. There is still no unified standard for local treatment and systemic treatment for advanced patients, and its efficacy is still controversial. Systemic treatment including platinum drugs can benefit some patients. The potential value of targeted therapy and immunotherapy in the treatment of advanced cHCC-CC patients has been highlighted. The introduction of multidisciplinary diagnosis and treatment model has provided a strong guarantee for the comprehensive treatment of patients, and the development of xenogenetic model and multi-omics technology has provided a considerable prospect for the realization of individualized treatment for patients. The present situation and progress of diagnosis and treatment of cHCC-CC are discussed in order to provide reference for clinical practice.
